Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
Affiliation
The Christie NHS Foundation Trust, Manchester, UK. Electronic address: anna.tran@christie.nhs.uk.Issue Date
2013-07-09
Metadata
Show full item recordAbstract
Routine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.Citation
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2013.05.030PubMed ID
23849172Type
ArticleLanguage
enISSN
1879-0887ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2013.05.030
Scopus Count
Collections
Related articles
- Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
- Authors: Kollmeier MA, Stock RG, Stone N
- Issue date: 2003 Nov 1
- Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
- Authors: Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E
- Issue date: 2002 Mar 1
- Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
- Authors: Brachman DG, Thomas T, Hilbe J, Beyer DC
- Issue date: 2000 Aug 1
- Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
- Authors: Wong WW, Schild SE, Vora SA, Halyard MY
- Issue date: 2004 Sep 1
- The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
- Authors: Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R
- Issue date: 2008 Jun 4